


## IN THIS ISSUE

- Welcome
- Universal Medicines List
- Working Group Meeting
- Clinical Leadership Group
- Medication Chart Standards
- Maori Health Advisor
- Evaluation of the SMM Programme
- Legislative Issues
- Stakeholder Engagement



## CONTACT US

For more information on the Safe Medication Management Programme please contact:

Clare Kirk  
Programme Lead  
Clare.kirk@huttvalleydhd.org.nz  
Phone 04 5666 999 ext 2571

## WELCOME

Kia ora and welcome to the third edition of the Safe Medication Management Programme (SMM Programme) newsletter.

The SMM Programme is making excellent progress as the programme team steadily works through the planning stages of each work stream.

The SMM Programme requires the support of the health and disability sector to be successful and the programme team has begun an extensive engagement programme to seek the input of stakeholders from across the sector.

We are about to update our website to include a greater range of resources and to give people better ability to comment on any aspect of the programme and we will keep you updated about this as it happens.

## UNIVERSAL MEDICINES LIST

The Safe Medication Management Programme is working with key pharmacy stakeholders on a Universal Medicines List for New Zealand.

The Universal Medicine List is a foundation for safe medication management. It links key medicines information resources used in the sector today to a common list of medicines and standardises the terms used to refer to medicines.

It ensures that there is a common understanding of core information at the pack and individual dose level including the generic (medicine) and related brand (product) names given to individual medicines as well as therapeutic group, dose form and strength, and active ingredient details.

Other medicine information resources can link to the Universal Medicines List.

The Universal Medicines List will allow systems to be developed to better support quality and safe prescribing, dispensing and administering of medication and to establish and maintain an accurate patient's medication history.

## WORKING GROUP MEETING

A combined Working Group meeting was held on 20 October in Wellington to take a collective look at the issues and opportunities being faced by the SMM Programme. It was very encouraging to see all 21 DHBs represented within the four sub project Working Groups.

The meeting focused very much on the need for the SMM Programme to be clinician led with a focus on better outcomes for consumers.

The initial focus is in the hospital setting and the interface with

## STEERING GROUP

**Chai Chuah**

Lead Chief Executive Officer

**Chris Fleming**

Supporting Chief Executive Officer

**Cheyne Chalmers**

Director of Nursing

**Anne McLean**

Chief Operating Officer

**Nick Lanigan**

Chief Information Officer

**Mary Seddon**

Quality Improvement Committee

**Elizabeth Plant (PSNZ)**

Safe and Quality Use of  
Medicine Group

**Helen Lockyer**

Ministry of Health

**Billy Allan (NZHPA)**

Chief Pharmacist

**Anne Kemp**

Quality & Risk Manager

**Adam McRae**

Safe and Quality Use of  
Medicine Group

**Keith Carey-Smith**

GP Liaison

**Tim Maling**

Chief Medical Officer  
Representative

**Paul Cressey**

Deputy Chair man Counties  
Manukau DHB

**Grant Taylor**

Chief Information Officer

**Barbara Holland**

Consumer

**Jean Park**

Consumer

**Erina Rewi**

Maori Health Advisor

Primary Care.

Primary Care stakeholders from the NZ College of GPs, the Independent Practitioner's Association Council (IPAC), and a GP Liaison attended the meeting along with consumer representatives.

## CLINICAL LEADERSHIP GROUP

The Safe and Quality Use of Medicine Group (SQUM) has been asked by the SMM Programme Steering Group to facilitate the formation of a Clinical Leadership Group.

This group will be made up of health professionals who will provide high-level guidance to the Steering Group and the programme team.

## MEDICATION CHART STANDARDS

The Medication Chart / E Prescribing Working Group has been making good progress on medication chart standards for New Zealand hospitals. The group has identified draft standards and is now working with Standards New Zealand to format these draft standards into a document. An example chart that meets the draft standards will be developed. The draft standards will be endorsed by the Clinical Leadership Group and then approved by the SMM Programme Steering Group.

## MAORI HEALTH ADVISOR

Erina Rewi has been appointed to the SMM Programme Steering Group as the Maori Health Advisor.

Erina is the Programme Director, Maori Health, at Southland District Health Board. She has a

a nursing degree and is of Kai Tahu, Ngati Kahungunu (Iwi).

## EVALUATION OF THE SMM PROGRAMME

Work has begun on developing the criteria by which the SMM Programme will be evaluated.

It is important to evaluate the success of the programme and to provide a platform for continual audit and improvement.

As a result of this work a framework will be established to rigorously assess and monitor the programme's outcomes.

## LEGISLATIVE ISSUES

The SMM Programme team has engaged the DHB General Counsel Group to review medicine regulatory barriers that the SMM Programme could face.

Potential legislative issues include the need for a doctor's signature on a prescription.

## STAKEHOLDER ENGAGEMENT

The SMM team have met and spoken with a number of key stakeholders over the last month including the Pharmaceutical Society, PHARMAC and the Pharmacy Guild.

Members of the SMM team will present to the Boards of the Pharmaceutical Society of NZ and PHARMAC in November and also the National Chief Medical Officer's group.

Communication with clinical stakeholders is essential to the success of the programme.